In a controversial move, the FDA has quietly removed its draft guidance on clinical trial diversity, sparking concerns over inclusivity.

Systemic barriers rooted in race, gender, and disability result in significant economic and social inequities for disabled women of color.

Diversity action plans aim to make rare disease clinical trials more inclusive and enhance treatment outcomes.